Bateman and DIAN-TU participant (IMAGE)

WashU Medicine

Bateman and DIAN-TU participant

Caption

Randall Bateman, MD, director of the Dominantly Inherited Alzheimer Network-Trials Unit (DIAN-TU), an ongoing international clinical trial to evaluate experimental Alzheimer's drugs, speaks with DIAN-TU participant Taylor Hutton. One of the drugs tested in the DIAN-TU, gantenerumab, improved biomarkers of disease despite unclear cognitive effects, prompting study leaders to offer participants the option of continuing to receive the drug and participate in follow-up examinations as part of a so-called open label extension.

Credit

Matt Miller

Usage Restrictions

This image is to be used in accordance with the mission, policies and guidelines of Washington University in St. Louis. Visit https://wustl.edu/about/compliance-policies/media-policies/multimedia-use/ for more information.

License

Licensed content

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.